Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia
Free accessResearch articleFirst published online February, 2013
Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia
The objective of our study was to compare two different central nervous system penetration- effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients.
Methods
We performed a cross-sectional single cohort study, consecutively enrolled during routine outpatient visits. HIV-infected subjects on antiretroviral therapy with plasma HIV RNA<50 copies/ml were included. A neuropsy-chological battery was administered. Each patient was classified as cognitively impaired on the basis of results obtained in age-, gender-, education- and nationality-matched healthy HIV-negative subjects. Self-reported adherence to antiviral therapy was measured on a 0–100 visual analogue scale. CPE rank was calculated for each antiretroviral regimen based on rules proposed by the CHARTER group in the 2008 original version (orCPE rank) and the 2010 revised version (revCPE rank). Neuroeffectiveness categories were analysed based on cutoffs of ≥1.5 (orCPE rank) or ≥6 (revCPE rank).
Results
A total of 101 patients were enrolled (66% male, median age 47 years, median education 13 years); mean adherence was 81%. orCPE rank ≥1.5 and revCPE rank ≥6 were observed in 85.0% and 78.2% of patients, respectively (P=0.31). Asymptomatic neurocognitive impairment (ANI) was diagnosed in 50 (49.5%) subjects. In a multivariable model, after adjusting for nationality, adherence and nadir CD4+ T-cell count, orCPE rank did not show an association with cognitive performance (P=0.704). By contrast, patients with revCPE rank ≥6 (OR 0.32, 95% CI 0.11, 0.95; P=0.039) and adherence ≥80% (OR 0.39, 95% CI 0.15, 0.99; P=0.047) showed a decreased risk of cognitive impairment.
Conclusions
A high prevalence of ANI was observed in virologically suppressed HIV-infected individuals. The revCPE rank showed improved association with neurocognitive dysfunction over the orCPE rank. Moreover, a relationship between cognitive impairment and adherence to antiretroviral therapy was found.
References
1.
PalellaF.J., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med1998; 338: 853–860.
2.
AntinoriA., ArendtG., BeckerJ.T.Update research for HIV-associated neurocognitive disorders. Neurology2007; 69: 1789–1799.
3.
SimioniS., CavassiniM., AnnoniJ.M.Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS2010; 24: 1243–1250.
4.
HeatonR.K., CliffordD.B., FranklinD.R.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology2010; 75: 2087–2096.
5.
CysiqueL.A., VaidaF., LetendreS.Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology2009; 73: 342–348.
6.
FerrandoS.J., RabkinJ.G., Van GorpW.G.Longitudinal improvement in psychomotor processing is associated with potent antiretroviral therapy in HIV infection. J Neuropsychiatry Clin Neurosci2003; 15: 208–214.
7.
BrewB.J., CroweS.M., LandayA.Neurodegeneration and aging in the HAART era. J Neuroimmune Pharmacol2009; 4: 163–174.
8.
ValcourV., ShikumaC., ShiramizuB.Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology2004; 63: 822–827.
9.
DeeksS.G.Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med2009; 17: 118–123.
10.
FortonD.M., Taylor-RobinsonS.D., ThomasH.C.Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat2003; 10: 81–86.
11.
FabbianiM., CiccarelliN., TanaM.Cardiovascular risk factors and carotid intima-media thickness are associated to lower cognitive performance in HIV-infected patients. HIV Med2012; doi: 10.1111/j.1468-1293.2012.01044.x.
12.
EttenhoferM.L., HinkinC.H., CastellonS.A.Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry2009; 17: 281–290.
13.
CysiqueL.A., BrewB.J.Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev2009; 19: 169–185.
14.
CanestriA., LescureF.X., JaureguiberryS.Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis2010; 50: 773–778.
15.
EdénA., FuchsD., HagbergL.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis2010; 202: 1819–1825.
16.
LetendreS.M., Marquie-BeckJ., CapparelliE.Validation of the CNS penetretion-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol2008; 65: 65–70.
17.
KoopmansP.P., EllisR., BestB.M.Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Neth J Med2009; 67: 206–211.
18.
CysiqueL.A., MaruffP., BrewB.J.Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology2006; 66: 1447–1450.
19.
TozziV., BalestraP., BellagambaR.Persistence of neuropsychological deficits despite long-term HAART in patients with HIV-related neurocognitive impairment. Prevalence and risk factors. J Acquir Immune Defic Syndr2007; 45: 174–182.
20.
TozziV., BalestraP., SalvatoriM.F.Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr2009; 52: 56–63.
21.
MarraC.M., ZhaoY., CliffordD.B.Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS2009; 23: 1359–1366.
22.
LetendreS., FitzSimonsC., EllisR.Correlates of CSF viral loads in 1221 volunteers in the CHARTER Cohort.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 172.
23.
CiccarelliN., FabbianiM., Di GiambenedettoS.Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology2011; 76: 1403–1409.
24.
Crum-CianfloneN.F., MooreD., LetendreS.An early diagnosed and treated HIV cohort shows low rates of neurocognitive impairment.19th Conference on Retrovirus and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Abstract 500.
25.
AntinoriA., LorenziniP., GiancolaM.L.Antiretroviral CNS penetration effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma.18th Conference on Retrovirus and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 426.
26.
MurriR., CingolaniA., De LucaA.Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. J Acquir Immune Defic Syndr2010; 55: 411–412.
27.
CapitaniE., LaiaconaM.Composite neuropsychological batteries and demographic correction: standardization based on equivalent scores, with a review of published data. J Clin Exp Neuropsychol1997; 19: 795–809.
YilmazA., IzadkhashtiA., PriceR.W.Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses2009; 25: 457–461.
GarveyL., SurendrakumarV., WinstonA.Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials2011; 12: 333–338.
LovejoyT.I., SuhrJ.A.The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med2009; 32: 389–405.
35.
AndradeA.S., McGruderH.F., WuA.W.Programmable prompting device improves adherence to highly active antiretroviral therapy inHIV-infected subjects with memory impairment. Clin Infect Dis2005; 41: 875–882.
36.
WrightM.J., WooE., FoleyJ.Antiretroviral adherence and the nature of HIV-associated verbal memory impairment. J Neuropsychiatry Clin Neurosci2011; 23: 324–331.
37.
McManusH., LiP.C., NolanD.Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?HIV Med2011; 12: 610–619.
